Moody Aldrich Partners LLC purchased a new position in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) during the second quarter, Holdings Channel reports. The institutional investor purchased 55,210 shares of the company’s stock, valued at approximately $1,286,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of VIVO. State Street Corp lifted its stake in shares of Meridian Bioscience by 14.9% during the 1st quarter. State Street Corp now owns 1,835,735 shares of the company’s stock worth $15,420,000 after purchasing an additional 237,787 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Meridian Bioscience by 2.5% in the first quarter. Geode Capital Management LLC now owns 883,776 shares of the company’s stock valued at $7,423,000 after purchasing an additional 21,482 shares during the period. Nuveen Asset Management LLC grew its holdings in shares of Meridian Bioscience by 47.0% in the first quarter. Nuveen Asset Management LLC now owns 764,903 shares of the company’s stock valued at $6,425,000 after purchasing an additional 244,478 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Meridian Bioscience by 162.5% in the first quarter. JPMorgan Chase & Co. now owns 679,518 shares of the company’s stock valued at $5,709,000 after purchasing an additional 420,681 shares during the period. Finally, Acadian Asset Management LLC increased its position in shares of Meridian Bioscience by 9.4% during the first quarter. Acadian Asset Management LLC now owns 672,416 shares of the company’s stock valued at $5,645,000 after acquiring an additional 57,882 shares during the last quarter. 82.60% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have issued reports on VIVO. ValuEngine lowered Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Friday, May 1st. BidaskClub upgraded shares of Meridian Bioscience from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 18th. HC Wainwright started coverage on shares of Meridian Bioscience in a research note on Monday, July 27th. They issued a “buy” rating and a $34.00 price objective for the company. William Blair upgraded shares of Meridian Bioscience from a “market perform” rating to an “outperform” rating in a research note on Monday, May 11th. Finally, TheStreet raised shares of Meridian Bioscience from a “c” rating to a “b” rating in a report on Thursday, May 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $17.25.

NASDAQ:VIVO traded down $0.46 on Friday, hitting $24.49. 501,820 shares of the stock were exchanged, compared to its average volume of 509,348. The company has a current ratio of 3.61, a quick ratio of 2.52 and a debt-to-equity ratio of 0.24. Meridian Bioscience, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $25.88. The stock has a market cap of $1.05 billion, a PE ratio of 39.50 and a beta of 0.94. The stock has a fifty day moving average of $22.04 and a 200-day moving average of $13.42.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Friday, May 8th. The company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.15. Meridian Bioscience had a return on equity of 13.59% and a net margin of 10.47%. The firm had revenue of $57.30 million during the quarter, compared to the consensus estimate of $57.00 million. As a group, analysts predict that Meridian Bioscience, Inc. will post 0.74 earnings per share for the current year.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Further Reading: How a Back-End Load Mutual Fund Works

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.